- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05794165
Antithrombin to Improve Thromboprophylaxis and Reduce the Incidence of Trauma-Related Venous Thromboembolism (TRAIT)
April 19, 2024 updated by: Bryan Cotton, The University of Texas Health Science Center, Houston
Antithrombin to Improve Thromboprophylaxis and Reduce the Incidence of Trauma-Related Venous Thromboembolism (TRAIT)
The purpose of this study is to determine if additional interventions will assist with decreasing the risk and/or severity of thromboembolism (clotting complications) in patients who have experienced a major traumatic event.
Study Overview
Status
Enrolling by invitation
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
314
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Bryan A Cotton, MD
- Phone Number: 713-500-7187
- Email: Bryan.A.Cotton@uth.tmc.edu
Study Contact Backup
- Name: Jeanette M Podbielski
- Phone Number: 832-656-9797
- Email: Jeanette.M.Podbielski@uth.tmc.edu
Study Locations
-
-
Texas
-
Houston, Texas, United States, 77030
- The University of Texas Health Science Center at Houston
-
Contact:
- Bryan A Cotton, MD
- Phone Number: 713-500-7187
- Email: Bryan.A.Cotton@uth.tmc.edu
-
Contact:
- Jeanette M Podbielski
- Phone Number: 832-656-9797
- Email: Jeanette.M.Podbielski@uth.tmc.edu
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Highest level of trauma activation or upgrade to highest level
- Polytraumatic injuries OR pelvic/long bone fracture
- Admission to trauma ICU or Surgical Intermediate Care Unit (SIMU)
- Informed consent obtained
Exclusion Criteria:
- Prisoners (defined as those directly admitted from correctional facility)
- Known or suspected pregnancy
- ≥ 20% total body surface area (TBSA) burned
- Nonsurvivable head injuries
- Known hematologic or immunologic disorders
- Known prehospital anticoagulant use
- Patients initially placed on unfractionated heparin for thromboprophylaxis
- Known allergy to Antithrombin or it's components
- Enrollment in another interventional study unless approved by Trial Principal Investigator
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo
|
Normal Saline will be given as one time IV before the 3rd dose of Enoxaparin.
The dose will be based on patient weight.
|
Experimental: Thrombate infusion
|
Bolus intravenous infusion of Thrombate will be given to achieve antithrombin (AT) activity levels at 150% before the 3rd dose of Enoxaparin.
The dose will be based on patient weight.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Number of participants with incidences of venous thromboembolism (VTE )
Time Frame: 14 days post hospital admission
|
14 days post hospital admission
|
Number of participants with incidence of antifactor Xa (anti-FXa) of ≥0.2 IU/mL
Time Frame: 14 days post hospital admission
|
14 days post hospital admission
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Time taken to achieve anti-FXa of ≥0.2 IU/mL
Time Frame: 14 days post hospital admission
|
14 days post hospital admission
|
Number of enoxaparin dose escalations
Time Frame: from the time of hospital admission to the time of hospital discharge or 30 days (whichever occurs first)
|
from the time of hospital admission to the time of hospital discharge or 30 days (whichever occurs first)
|
Number of incidences of participants with other thrombotic complications (arterial thrombosis, myocardial infarction, stroke)
Time Frame: from the time of hospital admission to the time of hospital discharge or 30 days (whichever occurs first)
|
from the time of hospital admission to the time of hospital discharge or 30 days (whichever occurs first)
|
Number of incidences of participants with bleeding events (interoperative bleeding, abdominal bleeding)
Time Frame: from the time of hospital admission to the time of hospital discharge or 30 days (whichever occurs first)
|
from the time of hospital admission to the time of hospital discharge or 30 days (whichever occurs first)
|
Number of hospital free days
Time Frame: from the time of hospital admission to the time of hospital discharge or 30 days (whichever occurs first)
|
from the time of hospital admission to the time of hospital discharge or 30 days (whichever occurs first)
|
Number of Ventilator free days
Time Frame: from the time of hospital admission to the time of hospital discharge or 30 days (whichever occurs first)
|
from the time of hospital admission to the time of hospital discharge or 30 days (whichever occurs first)
|
Number of ICU free days
Time Frame: from the time of hospital admission to the time of hospital discharge or 30 days (whichever occurs first)
|
from the time of hospital admission to the time of hospital discharge or 30 days (whichever occurs first)
|
Level of Anti-FXa
Time Frame: from the time of hospital admission up to hospital day 7
|
from the time of hospital admission up to hospital day 7
|
Antithrombin (AT) activity level
Time Frame: from the time of hospital admission up to hospital day 7
|
from the time of hospital admission up to hospital day 7
|
Change in level of the endothelial marker syndecan-1 as assessed by a blood test
Time Frame: time of hospital admission, day1, day2, day 3, day 4, day 5, day6, day 7
|
time of hospital admission, day1, day2, day 3, day 4, day 5, day6, day 7
|
Change in level of the endothelial marker thrombomodulin as assessed by a blood test
Time Frame: From the time of hospital admission to day 7
|
From the time of hospital admission to day 7
|
Change in level of Inflammatory marker Tumor necrosis factor alpha (TNFα) as assessed by a blood test
Time Frame: From time of hospital admission to day 7
|
From time of hospital admission to day 7
|
Change in level of Inflammatory marker Interleukin-8 (IL-8) as assessed by a blood test
Time Frame: From time of hospital admission to day 7
|
From time of hospital admission to day 7
|
Change in level of Inflammatory marker Interleukin-6(IL-6) as assessed by a blood test
Time Frame: time of hospital admission, day1, day2, day 3, day 4, day 5, day6, day 7
|
time of hospital admission, day1, day2, day 3, day 4, day 5, day6, day 7
|
Change in level of Inflammatory marker Interleukin-1 beta (IL1b) as assessed by a blood test
Time Frame: From time of hospital admission to day 7
|
From time of hospital admission to day 7
|
Change in level of Inflammatory marker Interleukin-1 alpha (IL1a) as assessed by a blood test
Time Frame: From time of hospital admission to day 7
|
From time of hospital admission to day 7
|
Change in level of Inflammatory marker Interferon -gamma (INFg) as assessed by a blood test
Time Frame: From time of hospital admission to day 7
|
From time of hospital admission to day 7
|
Number of participants with In-hospital mortality
Time Frame: from the time of hospital admission to the time of hospital discharge or 30 days (whichever occurs first)
|
from the time of hospital admission to the time of hospital discharge or 30 days (whichever occurs first)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Investigators
- Principal Investigator: Bryan A Cotton, MD, The University of Texas Health Science Center, Houston
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
September 5, 2023
Primary Completion (Estimated)
November 1, 2026
Study Completion (Estimated)
March 1, 2027
Study Registration Dates
First Submitted
March 14, 2023
First Submitted That Met QC Criteria
March 28, 2023
First Posted (Actual)
April 3, 2023
Study Record Updates
Last Update Posted (Actual)
April 23, 2024
Last Update Submitted That Met QC Criteria
April 19, 2024
Last Verified
April 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- HSC-MS-22-1102
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Thromboembolism
-
BayerWithdrawnTotal Hip Replacement | Total Knee Replacement | Prophylaxis, Thromboembolism, Venous
-
Northwell HealthCompletedVenous Thromboembolism | Arterial ThromboembolismUnited States
-
University Hospital, BrestRecruitingVenous Thromboembolism (VTE)France
-
University of ArizonaRecruitingPediatric Venous ThromboembolismUnited States
-
National Taiwan University HospitalUnknownDeep Venous ThromboembolismTaiwan
-
Ya-Wei XuFirst Affiliated Hospital, Sun Yat-Sen University; Nanfang Hospital of Southern...RecruitingVenous Thromboembolism (VTE)China
-
Bristol-Myers SquibbCompletedVenous Thromboembolism (VTE)United States
-
BayerCompletedTreatment of Venous ThromboembolismJapan
-
Azidus BrasilUnknownPrevention of Venous ThromboembolismBrazil
-
Fadoi Foundation, ItalyCompletedPrevention of Venous ThromboembolismItaly
Clinical Trials on Thrombate infusion
-
Enrique GinzburgGrifols Biologicals, LLCTerminatedCovid19 | Antithrombin III DeficiencyUnited States
-
The University of Texas Health Science Center,...United States Department of Defense; U.S. Army Medical Research and Development...Active, not recruitingTBI (Traumatic Brain Injury) | Brain Injuries, Traumatic | Brain Injuries, AcuteUnited States
-
Jianming TanUnknownOsteochondritis of the Femoral HeadChina
-
Bispebjerg HospitalPsychiatric Centre RigshospitaletCompletedCognitive Change | Type2 Diabetes | KetonemiaDenmark
-
Hospital Universitari Vall d'Hebron Research InstituteCompleted
-
Dompé Farmaceutici S.p.ACompletedKidney Diseases | Ischemia-Reperfusion InjuryUnited States, France, Italy, Spain
-
Far Eastern Memorial HospitalRecruitingHysteroscopic MyomectomyTaiwan
-
Jozef BartunekKing's College LondonTerminatedAcute Myocardial InfarctionNetherlands, France, Belgium, United Kingdom
-
Yale UniversityWithdrawnOvarian Hyperstimulation SyndromeUnited States